Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Deciphera Pharmaceuticals, Inc.
  6. News
  7. Summary
    DCPH   US24344T1016

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  05/16 04:00:01 pm EDT
10.62 USD   +3.01%
05/04TRANSCRIPT : Deciphera Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/04Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Deciphera to Cut Workforce by 35%; to Discontinue Rebastinib Program; to Extend Cash Runway into 2024

11/30/2021 | 09:00am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about DECIPHERA PHARMACEUTICALS, INC.
05/04TRANSCRIPT : Deciphera Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04DECIPHERA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
05/04Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Ma..
CI
05/04Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q1 Revenue $29.2M, vs. Street Est..
MT
05/04Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q1 Loss $-0.80, vs. Street Est of..
MT
05/04Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
BU
05/02Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-..
AQ
05/02Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Con..
BU
04/29Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-..
BU
04/28DECIPHERA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial St..
AQ
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 126 M - -
Net income 2022 -178 M - -
Net cash 2022 359 M - -
P/E ratio 2022 -3,98x
Yield 2022 -
Capitalization 727 M 727 M -
EV / Sales 2022 2,93x
EV / Sales 2023 2,78x
Nbr of Employees 280
Free-Float 74,8%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 10,62 $
Average target price 11,38 $
Spread / Average Target 7,11%
EPS Revisions
Managers and Directors
Steven L. Hoerter President & Chief Executive Officer
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn President, Chief Executive Officer & Director
Stephen B. Ruddy Chief Technical Officer & SVP
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.8.70%727
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601